Arctigenin could be a powerful drug candidate for acute hepatitis through immune suppression.
Arctigenin protects against liver injury from acute hepatitis by suppressing immune cells in mice.
AI Summary
Key Findings
Abstract
As a phenylpropanoid and dibenzylbutyrolactone lignan present in medical plants, such as those used in traditional Chinese herbal medicine, including Arctium lappa (Niubang), arctigenin exhibits antimicrobial, anti-inflammatory, and anticancer activities. In this study, we investigated the protective role of arctigenin in Concanavalin A (ConA)-induced acute hepatitis in mice. Arctigenin remarkably reduced the congestion and necroinflammation of livers, and improved hepatic function (ALT and AST) in ConA-induced acute hepatitis in vivo. The infiltration of CD4 T, NKT and macrophages into the livers was found to be reduced with arctigenin treatment. Arctigenin suppressed ConA-induced T lymphocyte proliferations that might have resulted from enhanced IL-10 production by macrophages and CD4 T cells. These results suggested that arctigenin could be a powerful drug candidate for acute hepatitis through immune suppression.
Affiliation
Xixi Cheng
External References
- PubMed ID:
- 29579707
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.